“Dyadic is advancing its transition to ... These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ ...

A research team led by Prof. Hou Xingliang from the South China Botanical Garden of the Chinese Academy of Sciences has used ...

production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system," issued a press release on October 17, 2025, ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life ...

Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw ...